Dashboard
Manage Tickers

HOWLWerewolf Therapeutics, Inc.

Nasdaq werewolftx.com


$ 1.89 $ 0.04 (2.16 %)    

Friday, 09-Aug-2024 15:59:08 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 450.22 $ 2.34 (0.52 %)
DIA $ 395.16 $ 0.63 (0.16 %)
SPY $ 532.81 $ 2.34 (0.44 %)
TLT $ 96.28 $ 0.94 (0.99 %)
GLD $ 224.54 $ 0.55 (0.25 %)
$ 1.89
$ 1.87 x 100
$ 1.91 x 100
-- - --
$ 1.57 - $ 8.19
253,790
na
83.24M
$ 0.91
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2024 06-30-2024 10-Q
2 05-03-2024 03-31-2024 10-Q
3 03-07-2024 12-31-2023 10-K
4 11-14-2023 09-30-2023 10-Q
5 08-10-2023 06-30-2023 10-Q
6 05-11-2023 03-31-2023 10-Q
7 03-23-2023 12-31-2022 10-K
8 11-10-2022 09-30-2022 10-Q
9 08-11-2022 06-30-2022 10-Q
10 05-10-2022 03-31-2022 10-Q
11 03-24-2022 12-31-2021 10-K
12 11-10-2021 09-30-2021 10-Q
13 08-12-2021 06-30-2021 10-Q
14 06-10-2021 03-31-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

werewolf-therapeutics-q2-2024-gaap-eps-043-misses-037-estimate-sales-1143m-beat-842000k-estimate-cash-and-cash-equivalents-were-1353m-expected-to-provide-cash-runway-through-at-least-the-first-quarter-of-2026
Werewolf Therapeutics Q2 2024 GAAP EPS $(0...
08/08/2024 12:38:07

hc-wainwright--co-reiterates-buy-on-werewolf-therapeutics-maintains-15-price-target
HC Wainwright & Co. Reiterates Buy on Were...
07/02/2024 10:33:07

HC Wainwright & Co. analyst Andres Maldonado reiterates Werewolf Therapeutics (NASDAQ:HOWL) with a Buy and maintains $15...

jmp-securities-reiterates-market-outperform-on-werewolf-therapeutics-maintains-12-price-target
JMP Securities Reiterates Market Outperfor...
06/26/2024 16:05:54

JMP Securities analyst Reni Benjamin reiterates Werewolf Therapeutics (NASDAQ:HOWL) with a Market Outperform and maintains $...

where-werewolf-therapeutics-stands-with-analysts
Where Werewolf Therapeutics Stands With An...
06/26/2024 12:01:27

hc-wainwright--co-reiterates-buy-on-werewolf-therapeutics-maintains-15-price-target
HC Wainwright & Co. Reiterates Buy on Were...
06/26/2024 11:08:35

HC Wainwright & Co. analyst Andres Maldonado reiterates Werewolf Therapeutics (NASDAQ:HOWL) with a Buy and maintains $15...

werewolf-therapeutics-announced-initial-results-from-phase-1-trial-of-wtx-330-as-monotherapy-for-immunotherapy-insensitive-or-resistant-locally-advanced-or-metastatic-solid-tumors-or-non-hodgkin-lymphoma-additional-results-expected-in-q4-of-2024
Werewolf Therapeutics Announced Initial Re...
06/25/2024 11:11:59

jmp-securities-reiterates-market-outperform-on-werewolf-therapeutics-maintains-12-price-target
JMP Securities Reiterates Market Outperfor...
06/04/2024 12:23:15

JMP Securities analyst Reni Benjamin reiterates Werewolf Therapeutics (NASDAQ:HOWL) with a Market Outperform and maintains $...

12-health-care-stocks-moving-in-mondays-intraday-session
12 Health Care Stocks Moving In Monday's I...
06/03/2024 16:31:06

hc-wainwright--co-reiterates-buy-on-werewolf-therapeutics-maintains-15-price-target
HC Wainwright & Co. Reiterates Buy on Were...
06/03/2024 14:14:04

HC Wainwright & Co. analyst Andres Maldonado reiterates Werewolf Therapeutics (NASDAQ:HOWL) with a Buy and maintains $15...

critical-insights-from-werewolf-therapeutics-analyst-ratings-what-you-need-to-know
Critical Insights From Werewolf Therapeuti...
05/24/2024 13:00:40

hc-wainwright--co-reiterates-buy-on-werewolf-therapeutics-maintains-15-price-target
HC Wainwright & Co. Reiterates Buy on Were...
05/24/2024 10:53:04

HC Wainwright & Co. analyst Andres Maldonado reiterates Werewolf Therapeutics (NASDAQ:HOWL) with a Buy and maintains $15...

the-analyst-verdict-werewolf-therapeutics-in-the-eyes-of-4-experts
The Analyst Verdict: Werewolf Therapeutics...
05/06/2024 15:00:57

jmp-securities-reiterates-market-outperform-on-werewolf-therapeutics-maintains-12-price-target
JMP Securities Reiterates Market Outperfor...
05/06/2024 14:57:04

JMP Securities analyst Reni Benjamin reiterates Werewolf Therapeutics (NASDAQ:HOWL) with a Market Outperform and maintains $...

hc-wainwright--co-reiterates-buy-on-werewolf-therapeutics-maintains-15-price-target
HC Wainwright & Co. Reiterates Buy on Were...
05/06/2024 10:51:57

HC Wainwright & Co. analyst Andres Maldonado reiterates Werewolf Therapeutics (NASDAQ:HOWL) with a Buy and maintains $15...

werewolf-therapeutics-q1-eps-039-misses-035-estimate-sales-74200-miss-182m-estimate
Werewolf Therapeutics Q1 EPS $(0.39) Misse...
05/03/2024 11:19:18

Werewolf Therapeutics (NASDAQ:HOWL) reported quarterly losses of $(0.39) per share which missed the analyst consensus estimate ...

werewolf-therapeutics-announces-wtx-124-clinical-abstract-accepted-for-presentation-at-the-2024-asco-annual-meeting
Werewolf Therapeutics Announces WTX-124 Cl...
04/24/2024 14:05:50

Company to present an update of its ongoing monotherapy and combination Phase 1/1b study of WTX-124 in advanced or metastatic s...

werewolf-therapeutics-presents-first-preclinical-data-highlighting-il-10-indukine-molecules-as-potential-therapy-for-inflammatory-bowel-disease-at-aai-annual-meeting
Werewolf Therapeutics Presents First Precl...
04/23/2024 12:14:16

First Data Demonstrating Application of PREDATOR™ Platform in Immune-Mediated Diseases

werewolf-therapeutics-presents-preclinical-results-demonstrating-anti-tumor-effects-of-pro-inflammatory-cytokine-therapeutics-wtx-518-and-wtx-712-at-aacr-2024-annual-meeting
Werewolf Therapeutics Presents Preclinical...
04/05/2024 20:32:25

 WTX-518, a conditionally activated IL-18 INDUKINETM molecule that resists suppression by IL-18BP, led to complete tumor regres...

jmp-securities-initiates-coverage-on-werewolf-therapeutics-with-market-outperform-rating-announces-price-target-of-12
JMP Securities Initiates Coverage On Werew...
04/03/2024 08:47:37

JMP Securities analyst Reni Benjamin initiates coverage on Werewolf Therapeutics (NASDAQ:HOWL) with a Market Outperform rati...

hc-wainwright--co-maintains-buy-on-werewolf-therapeutics-maintains-15-price-target
HC Wainwright & Co. Maintains Buy on Werew...
03/07/2024 16:58:38

HC Wainwright & Co. analyst Andres Maldonado maintains Werewolf Therapeutics (NASDAQ:HOWL) with a Buy and maintains $15 ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION